Speakers

Co-Chairs

Dr. Leslie Fischer

Principal Patent Attorney
Sandoz (Princeton, NJ)

Co-Chairs’ Opening Remarks

August 5, 2020 • 9:00 am

Duane Marks

Assistant General Patent Counsel
Eli Lilly (Indianapolis, IN)

Section 101: Exploring the Realities of the New USPTO Guidance

August 5, 2020 • 2:00 pm

Speakers

Takanori Abe

Managing Partner
Abe & Partners (Osaka, Japan)

Written Description and Enablement in Antibody Arts: How Has the Scope of Claim Shifted in the U.S., Europe, and Japan?

August 5, 2020 • 11:20 am

Dorothy R. Auth Ph.D.

Partner
Cadwalader, Wickersham & Taft LLP (New York, NY)

Recent Developments Regarding License Agreements and Compulsory Licensing in the Life Sciences

August 6, 2020 • 9:15 am

Klaas Bisschop

Partner
Hogan Lovells (Amsterdam, NE)

Doctrine of Equivalents Analysis: Understanding How the Latest DoE Decisions Will Impact Future of Trends in Patent Law Protection in the U.S., Europe and Asia

August 6, 2020 • 11:00 am

Honorable Jacqueline Bonilla

Vice Chief Administrative
Judge, Patent Trial and Appeal Board
U.S. Patent and Trademark Office
(Invited)

PTAB Keynote Address

August 5, 2020 • 9:15 am

Heather Boussios

Assistant General Counsel – IP
Aptevo Therapeutics (Seattle, WA)

Written Description and Enablement in Antibody Arts: How Has the Scope of Claim Shifted in the U.S., Europe, and Japan?

August 5, 2020 • 11:20 am

Adrian Bradley

Partner
Cleveland Scott York (Thames Valley Reading, UK)

Workshop — Master Class on Drafting Life Sciences Patent Applications In the U.S., Europe, and Asia

August 4, 2020 • 1:30 pm

June Cohan

Legal Advisor, Office of Patent Legal Administration
U.S. Patent and Trademark Office (Alexandria, VA)

Section 101: Exploring the Realities of the New USPTO Guidance

August 5, 2020 • 2:00 pm

Nicola Dagg

Partner
Kirkland & Ellis (London, UK)

Written Description and Enablement in Antibody Arts: How Has the Scope of Claim Shifted in the U.S., Europe, and Japan?

August 5, 2020 • 11:20 am

Robin Ellis

Partner
Reddie & Grose GmbH

Exploring the Future of Patent Protection Through Artificial Intelligence

August 6, 2020 • 2:15 pm

James M. Gould

Counsel and Co-Chair – Pharmaceutical, Biopharma and Life Sciences
Ratner Prestia (Philadelphia, PA)
(Former Legal Director — IP Litigation at Merck & Co)

Recent Developments Regarding License Agreements and Compulsory Licensing in the Life Sciences

August 6, 2020 • 9:15 am

Henry Gu

Vice President, Chief IP Counsel
Akebia Therapeutics (Cambridge, MA)

Focus on Small Molecules: Harnessing the Power of Written Description and Enablement to Strengthen Patent Protection in the U.S. – Europe – China

August 5, 2020 • 10:20 am

Gabrielle E. Higgins

Partner
Ropes & Gray LLP (San Francisco, CA)

Discretionary Denials at the PTAB

August 5, 2020 • 12:15 pm

Dr. Sebastian Höpfner

Partner
German and European Patent and Trademark Attorney
Bird & Bird (Munich, Germany)

Inherency and Obviousness: Anticipating What’s Next Around the World

August 5, 2020 • 4:30 pm

Charlotte Jacobsen

Partner
Ropes & Gray (New York, NY)

Written Description and Enablement in Antibody Arts: How Has the Scope of Claim Shifted in the U.S., Europe, and Japan?

August 5, 2020 • 11:20 am

Tom Kowlaski

Partner
Duane Morris (New York, NY)

Ethical Obligations in Prosecution

August 6, 2020 • 3:00 pm

Forrester Liddle

Senior Director,
Head of Intellectual Property
Jounce Therapeutics (Cambridge, MA)

Inherency and Obviousness: Anticipating What’s Next Around the World

August 5, 2020 • 4:30 pm

John D. Livingstone

Partner
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP (Atlanta, GA)

Doctrine of Equivalents Analysis: Understanding How the Latest DoE Decisions Will Impact Future of Trends in Patent Law Protection in the U.S., Europe and Asia

August 6, 2020 • 11:00 am

Deborah Lu

Partner
Duane Morris (New York, NY)

Workshop — Master Class on Drafting Life Sciences Patent Applications In the U.S., Europe, and Asia

August 4, 2020 • 1:30 pm

Rachel Mumby

Senior Associate
Bristows LLP (London, UK)

Focus on Small Molecules: Harnessing the Power of Written Description and Enablement to Strengthen Patent Protection in the U.S. – Europe – China

August 5, 2020 • 10:20 am

Kevin E. Noonan, Ph. D.

Partner
McDonnell Boehnen Hulbert & Berghoff LLP (Chicago, IL)

Section 101: Exploring the Realities of the New USPTO Guidance

August 5, 2020 • 2:00 pm

Brendan M. O’Malley

Vice President, Head of Legal & IP
Corporate Secretary
Abeona Therapeutics Inc (New York, NY)

Recent Developments Regarding License Agreements and Compulsory Licensing in the Life Sciences

August 6, 2020 • 9:15 am

Filko Prugo

Partner
Ropes & Gray (New York, NY)

Inherency and Obviousness: Anticipating What’s Next Around the World

August 5, 2020 • 4:30 pm

Roberto Ribeiro

Partner
Daniel Law (Sao Paolo, Brazil)

Exploring the Future of Patent Protection Through Artificial Intelligence

August 6, 2020 • 2:15 pm

Roberto Rodrigues

Roberto Rodrigues

Attorney at Law
Licks Attorney (Rio de Janerio, BR)

Social Contracting: Understanding Its Impact on Patent litigation in Developing Countries

August 6, 2020 • 1:00 pm

Christina Schwarz

Partner
Venable LLP (New York, NY)

Navigating the Evolving Obviousness-Type Double Patenting Landscape

August 5, 2020 • 3:40 pm

Marina Volin

VP, General Counsel and Corporate Secretary
Amring Pharmaceuticals (Berwyn, PA)

Navigating the Evolving Obviousness-Type Double Patenting Landscape

August 5, 2020 • 3:40 pm

Mark Waddell

Co-Chair, Life Sciences; Chair, Patent Litigation & Counseling
Loeb & Loeb LLP (New York, NY)

Section 101: Exploring the Realities of the New USPTO Guidance

August 5, 2020 • 2:00 pm

Peter Waibel

Head US Patent Litigation
Novartis Pharmaceuticals Corporation (East Hanover, NJ)

Discretionary Denials at the PTAB

August 5, 2020 • 12:15 pm